Nurix Therapeutics Inc. Common stock (NRIX)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earnings power and a margin of safety. Nurix is a clinical-stage drug developer, so its value rests on pipeline prospects, not current profits. The filed record is mostly red: in fiscal 2023, the year ended 2023-11-30, net loss was $143.9M; in fiscal 2024, the year ended 2024-11-30, net loss was $193.6M; in fiscal 2025, the year ended 2025-11-30, net loss was $264.5M. Trailing free cash flow is -$304.5M, a FairStock FCF yield of -12.6% against the 2026-10-13 close of $22.13. FairStock also calculates P/E -6.40, P/B 5.70, ROE -80.30%, ROCE -40.06%, Piotroski F-Score 2/9, and a FairStock Score of 27/100. Its Lynch category is none because losses occurred in each of the last four years. The one bright spot is the filed fiscal Q3 2026, the quarter ended 2026-08-31, which reported revenue of $673.1M, net income of $549.8M, and diluted EPS of $4.73. If that is recurring, the picture changes dramatically. But neighboring quarters, fiscal Q2 2026, ended 2026-05-31, revenue $9.0M and net loss $89.5M; fiscal Q1 2026, ended 2026-02-28, revenue $6.3M and net loss $87.2M, show how unproven and lumpy the business is. The balance sheet has low debt, with D/E of 0.14, and FairStock's Altman Z-Score of 8.13 suggests low near-term insolvency risk on that measure. Still, at $22.13 the market already prices meaningful success. I would want proof that fiscal Q3 2026 is repeatable and cash burn is controlled before calling this a value opportunity.

In plain English: Nurix Therapeutics develops experimental medicines for cancer and inflammatory diseases. The business has mostly lost money and spent more cash than it took in, though one recent quarter showed a large profit. At $22.13, the stock looks expensive compared with that weak record unless the big quarter keeps repeating.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-08-31) · fiscal Q2 2026 10-Q (period ended 2026-05-31) · fiscal Q1 2026 10-Q (period ended 2026-02-28) · fiscal Q3 2025 10-Q (period ended 2025-08-31) · FY2025 10-K (period ended 2025-11-30) · FY2024 10-K (period ended 2024-11-30) · FY2023 10-K (period ended 2023-11-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer